Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
TNGX

TNGX - Tango Therapeutics, Inc. Stock Price, Fair Value and News

$17.32+0.17 (+0.99%)
Market Closed

16/100

TNGX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

16/100

TNGX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TNGX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TNGX Price Action

Last 7 days

2.2%

Last 30 days

37.4%

Last 90 days

85.2%

Trailing 12 Months

831.2%

TNGX RSI Chart

TNGX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TNGX Valuation

Market Cap

2.5B

Price/Earnings (Trailing)

-24.33

Price/Sales (Trailing)

39.62

EV/EBITDA

-25.19

Price/Free Cashflow

-17.66

TNGX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TNGX Fundamentals

TNGX Revenue

Revenue (TTM)

62.4M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

TNGX Earnings

Earnings (TTM)

-101.6M

Earnings Growth (Yr)

-2.86%

Earnings Growth (Qtr)

-343.95%

TNGX Profitability

EBT Margin

-162.85%

Return on Equity

-29.35%

Return on Assets

-25.48%

Free Cashflow Yield

-5.66%

TNGX Investor Care

Shares Dilution (1Y)

25.30%

Diluted EPS (TTM)

-0.87

TNGX Alerts

  • 3 major insider sales recently.
  • Big fall in Revenue (Y/Y)
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202541.0M24.3M66.5M62.4M
202437.2M42.5M43.4M42.1M
202324.9M33.7M37.5M36.5M
202236.4M24.0M24.2M24.9M
202118.8M29.9M31.6M37.0M
20200007.7M
Get all data in R, Python etc through our Historical Stock Data APIs

About Tango Therapeutics, Inc.

TNGX
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEtangotx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES110

Tango Therapeutics, Inc. Frequently Asked Questions

TNGX is the stock ticker symbol of Tango Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Tango Therapeutics, Inc. is 2.47 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, TNGX's PE ratio (Price to Earnings) is -24.33 and Price to Sales (PS) ratio is 39.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TNGX PE ratio will change depending on the future growth rate expectations of investors.